Alector/$ALEC
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Alector
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.
Ticker
$ALEC
Sector
Primary listing
Employees
156
Headquarters
Website
Alector Metrics
BasicAdvanced
$133M
-
-$1.08
0.66
-
Price and volume
Market cap
$133M
Beta
0.66
52-week high
$3.40
52-week low
$0.87
Average daily volume
2.3M
Financial strength
Current ratio
3.757
Quick ratio
3.64
Long term debt to equity
50.069
Total debt to equity
65.628
Profitability
EBITDA (TTM)
-115.693
Gross margin (TTM)
-169.29%
Net profit margin (TTM)
-156.03%
Operating margin (TTM)
-175.94%
Effective tax rate (TTM)
-0.04%
Revenue per employee (TTM)
$440,000
Management effectiveness
Return on assets (TTM)
-17.84%
Return on equity (TTM)
-121.98%
Valuation
Price to revenue (TTM)
1.77
Price to book
2.27
Price to tangible book (TTM)
2.27
Price to free cash flow (TTM)
-0.619
Free cash flow yield (TTM)
-161.66%
Free cash flow per share (TTM)
-1.972
Growth
Revenue change (TTM)
12.26%
Earnings per share change (TTM)
-36.80%
3-year revenue growth (CAGR)
-19.66%
3-year earnings per share growth (CAGR)
-13.50%
What the Analysts think about Alector
Analyst ratings (Buy, Hold, Sell) for Alector stock.
Alector Financial Performance
Revenues and expenses
Alector Earnings Performance
Company profitability
Alector News
AllArticlesVideos
ALEC Investors Have Opportunity to Join Alector, Inc. Fraud Investigation with the Schall Law Firm
Business Wire4 weeks ago
Clinical Failure Halts Alector's Dementia Program, Company Reduces Workforce
Benzinga2 months ago
Alector shares plunge after dementia drug fails to slow disease progression
Reuters2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Alector stock?
Alector (ALEC) has a market cap of $133M as of December 07, 2025.
What is the P/E ratio for Alector stock?
The price to earnings (P/E) ratio for Alector (ALEC) stock is 0 as of December 07, 2025.
Does Alector stock pay dividends?
No, Alector (ALEC) stock does not pay dividends to its shareholders as of December 07, 2025.
When is the next Alector dividend payment date?
Alector (ALEC) stock does not pay dividends to its shareholders.
What is the beta indicator for Alector?
Alector (ALEC) has a beta rating of 0.66. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.